Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine Maintenance in Extensive SCLC
NCT02039518Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Dec 2013
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in small cell lung cancer (SCLC) comparing Gemcitabine Arm with Observation Arm (2 arms). Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
gemcitabine
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02039518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02039518.